Growth velocity reduced with once-daily fluticasone furoate nasal spray in prepubescent children with perennial allergic rhinitis

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 4, 2014, Pages 421-427

  Lee, Laurie A ^a   Sterling, Richard ^b   Máspero, Jorge ^c   Clements, Diane ^a   Ellsworth, Anna ^a   Pedersen, Soren ^d  

^a GLAXOSMITHKLINE   (United States)

^b Department of Otolaryngology Carolina Research ^*  (United States)

^c CABA   (Argentina)

^d KOLDING HOSPITAL   (Denmark)

Author keywords

24 Hour urinary cortisol; Children; Intranasal corticosteroid; Placebo controlled; Randomized clinical trial; Stadiometry

Indexed keywords

CORTICOSTEROID; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; HYDROCORTISONE; IMMUNOGLOBULIN E; PLACEBO; ANDROSTANE DERIVATIVE; FLUTICASONE; NOSE SPRAY;

APPENDICITIS; ARTICLE; ASTHMA; CANCER INHIBITION; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; FEMALE; GASTROENTERITIS; GROWTH INHIBITION; GROWTH RATE; HEAD INJURY; HUMAN; HYDROCORTISONE URINE LEVEL; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOSITIS; OSTEOMYELITIS; PARALLEL DESIGN; PATIENT COMPLIANCE; PERENNIAL RHINITIS; PNEUMONIA; PREPUBERTY; RANDOMIZED CONTROLLED TRIAL; SKIN TEST; SYMPTOMATOLOGY; VIRAL RESPIRATORY TRACT INFECTION; BIOMETRY; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; FOLLOW UP; GROWTH; MEDICATION COMPLIANCE; PRESCHOOL CHILD; PUBERTY; RHINITIS, ALLERGIC, PERENNIAL; URINE;

ANDROSTADIENES; BIOMETRIC IDENTIFICATION; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GROWTH; HUMANS; HYDROCORTISONE; IMMUNOGLOBULIN E; MALE; MEDICATION ADHERENCE; NASAL SPRAYS; PUBERTY; RHINITIS, ALLERGIC, PERENNIAL; SKIN TESTS;

EID: 84904048372     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.04.008     Document Type: Article

References (17)

1. Wright A.L., Holberg C.J., Martinez F.D., Halonen M., Morgan W., Taussig L.M. Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics 1994, 94:895-901.
2. Meltzer E.O., Tripathy I., Máspero J.F., Wu W., Philpot E. Safety and tolerability of fluticasone furoate nasal spray once daily in paediatric patients aged 6-11 years with allergic rhinitis: subanalysis of three randomized, double-blind, placebo-controlled, multicentre studies. Clin Drug Investig 2009, 29:79-86.
3. Skoner D.P., Rachelefsky D.S., Meltzer E.O., Chervinsky P., Morris R.M., Seltzer J.M., et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000, 105:E23.
4. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. Food and Drug Administration guidance for industry, orally inhaled and intranasal corticosteroids: evaluation of the effects on growth in children. March 2007. http://www.fda.gov/cder/guidance/index.htm.
5. Meltzer E.O., Lee J., Tripathy I., Lim J., Ellsworth A., Philpot E. Efficacy and safety of once-daily fluticasone furoate nasal spray in children with seasonal allergic rhinitis treated for 2 wk. Pediatr Allergy Immunol 2009, 20:279-286.
6. Máspero J.F., Rosenblut A., Finn A., Lim J., Wu W., Philpot E. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol Head Neck 2008, 138:30-37.
7. Tripathy I., Levy A., Ratner P., Clements D., Wu W., Philpot E. HPA axis safety of fluticasone furoate nasal spray once daily in children with perennial allergic rhinitis. Pediatr Allergy Immunol 2009, 20:287-294.
8. Tanner J.M., Whitehouse R.H., Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children 1965. Arch Dis Child 1966, 41:454-635.
9. Tanner J.M., Whitehouse R.H., Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children 1965. I.Arch Dis Child 1965, 41:613-635.
10. Ahmet A., Kim H., Spier S. Adrenal suppression: a practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. Allergy Asthma Immunol 2011, 7:13.
11. Kazlauskaite R., Evans A.T., Villabona C.V., Abdu T.A., Ambrosi B., Atkinson A.B., et al. Corticotropin tests for hypothalamic-pituitary-adrenal insufficiency: a meta analysis. JClin Endocrinol Metab 2008, 93:4245-4253.
12. Murphy K., Uryniak T., Simpson B., O'Dowd L. Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. Ann Allergy Asthma Immunol 2006, 96:723-730.
13. Allen D.B., Meltzer E.O., Lemanske R.F., Philpot E.E., Faris M.A., Kral K.M., et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002, 23:407-413.
14. Wallace D.V., Dykewicz M.S., Bernstein D.I., Blessing-Moore J., Cox L., Khan D.A., et al. The diagnosis and management of rhinitis: an updated practice parameter. JAllergy Clin Immunol 2008, 122:S1-84.
15. Agertoft L., Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. NEngl J Med 2000, 343:1064-1069.
16. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Research Group. NEngl J Med 2000, 343:1054-1063.
17. Kelly H.W., Sternberg A.L., Lescher R., Fuhlbrigge A.L., Williams P., Zeiger R.S., et al. Effect of inhaled glucocorticoids in childhood on adult height. NEngl J Med 2012, 367:904-912.